We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Immutep is a biotechnology business based in Australia. Immutep shares (IMM) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Immutep has a trailing 12-month revenue of around $3.9 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.295 - $0.725 |
|---|---|
| 50-day moving average | $0.5087 |
| 200-day moving average | $0.5245 |
| Target price | $1.12 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.05 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.45
| 1 week (2022-01-13) | -4.26% |
|---|---|
| 1 month (2021-12-21) | -6.25% |
| 3 months (2021-10-21) | -22.41% |
| 6 months (2021-07-21) | -10.00% |
| 1 year (2021-01-21) | 4.65% |
|---|---|
| 2 years (2020-01-20) | 50.00% |
| 3 years (2019-01-18) | -85.84% |
| 5 years (2017-01-20) | -87.42% |
| Revenue TTM | $3.9 million |
|---|---|
| Gross profit TTM | $-13,373,974 |
| Return on assets TTM | -19.1% |
| Return on equity TTM | -56.12% |
| Profit margin | 0% |
| Book value | 0.098 |
| Market capitalisation | $340.4 million |
TTM: trailing 12 months
We're not expecting Immutep to pay a dividend over the next 12 months.
Immutep 's shares were split on a 1:10 basis on 4 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep 's share price.
Over the last 12 months, Immutep 's shares have ranged in value from as little as $0.295 up to $0.725. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Immutep 's is 1.536. This would suggest that Immutep 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Don't fall for the scam artists when you're trying to protect your health - here's what to check.
Here's where you can book COVID-19 at-home tests approved for travel and how they work.
We've rounded up everything you need to nail the 'date-worthy' makeup look, including some affordable dupes.
Designed for big companies, this Amex charge card offers a mix of management tools and perks – including a 100,000 bonus Membership Rewards offer.
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
We tried the viral Milk Makeup Hydro Grip Primer and spoiler alert, it's the bee's knees.
Drac and the Pack are back, like you’ve never seen them before.
A delightful compact vacuum with an unjustifiable price.
A new player enters the Australian sports broadcast market.
The Amazon Echo Buds 2 are a solid addition to your earholes if you’re already integrated in the Alexa ecosystem. But if you’re not, its hard to find anything here that really stands out.
